
We assessed the association of detectable antibody response to COVID‐19 vaccination with factors including B‐cell depletion in rituximab treated patients. A retrospective chart review of rituximab treated adult patients who completed mRNA vaccination for SARS‐CoV‐2 was conducted. Primary outcome was presence and strength of serologic antibody response to vaccination. Comparisons between those with and without detectable serologic response were calculated using T‐tests, Fisher's exact test and Wilcoxon rank sum tests. Negative and positive predictive value was calculated between serologic response and B‐cell reconstitution status...
Like
Save
Share